KPT-8752

KPT-8752 is a small molecule allosteric modulator of p21-activated kinase 4 (PAK4) developed by Karyopharm Therapeutics. It belongs to a series of PAK4 allosteric modulators (PAMs) that include the clinical candidate KPT-9274. Preclinical studies in renal cell carcinoma (RCC) models have shown that KPT-8752 reduces cell viability, induces apoptosis, and triggers G2/M phase arrest in cancer cells. Its mechanism of action involves the reduction of phospho-PAK4 levels and the subsequent downregulation of key oncogenic signaling proteins such as phospho-beta-catenin, c-Myc, and cyclin D1. While KPT-8752 has been utilized in early-stage research to validate the PAK4 pathway as a therapeutic target, KPT-9274 has been the primary focus for clinical development.